|
|
Article: FDA APPROVES ILEX, MILLENNIUM ANTIBODY CAMPATH FOR LEUKEMIA.
- Article from:
- BIOWORLD Today
- Article date:
- May 9, 2001
- Author:
CopyrightCOPYRIGHT 2001 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ILEX Oncology Inc. and Millennium Pharmaceuticals Inc. received FDA approval to market Campath, a leukemia drug expected to generate upwards of $68 million in its first full year of worldwide sales.
Campath (alemtuzumab) will be marketed in the U.S. by Berlex Laboratories Inc., a U.S. affiliate of Germany-based Schering AG. Berlex, ILEX and Millennium will equally divide the U.S. profits and expenses related to Campath, company officials said. The drug is approved as a treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) who have been treated with alkylating agents and have failed fludarabine therapy.
Although the companies did not ...